XTL Biopharmaceuticals Ltd ADR (XTLB) Stock Analysis

XTL Biopharmaceuticals Ltd ADR (XTLB) is a publicly traded company in the HEALTHCARE sector. It trades at $2.29, carries a market capitalization of $5.77M. This page summarizes the public market data, fundamentals, and frequently asked questions for XTLB, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

XTL Biopharmaceuticals Ltd ADR currently has a Bearish sentiment score of -0.67.

About XTL Biopharmaceuticals Ltd ADR

XTL Biopharmaceuticals Ltd. is an innovative biopharmaceutical company headquartered in Ramat Gan, Israel, focusing on developing and commercializing novel therapeutic solutions for autoimmune diseases. With a robust pipeline and proprietary technologies, XTL is committed to addressing significant unmet medical needs and improving patient outcomes. The company's strategic focus on emerging healthcare opportunities positions it favorably within the dynamic biopharma sector, making it a compell...

GNG Research Analysis

GNG Research scores XTL Biopharmaceuticals Ltd ADR (XTLB) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for XTLB.

Frequently Asked Questions

Does XTLB pay dividends?

XTL Biopharmaceuticals Ltd ADR (XTLB) does not currently pay a regular dividend.

What is XTLB's market cap?

XTL Biopharmaceuticals Ltd ADR (XTLB) has a market capitalization of $5.77M with a current stock price of $2.29.